Advertisement
KRYS vs PTGX
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KRYS is a Buy and PTGX is a Buy.
KRYS sees its Stochastic Oscillator recovers from oversold territory
On October 28, 2026, the Stochastic Oscillator for KRYS moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 54 instances where the indicator left the oversold zone. In 43 of the 54 cases the stock moved higher in the following days. This puts the odds of a move higher at over 80%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +1.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where KRYS advanced for three days, in 258 of 326 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
KRYS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on KRYS as a result. In 78 of 105 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.
The Moving Average Convergence Divergence Histogram (MACD) for KRYS turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 56 similar instances when the indicator turned negative. In 41 of the 56 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where KRYS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 71%.
The Aroon Indicator for KRYS entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 2 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 9 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 46 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 54 (best 1 - 100 worst), indicating steady price growth. KRYS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (6.553) is normal, around the industry mean (3.498). P/E Ratio (36.382) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (23.202) is also within normal values, averaging (440.869).
PTGX in upward trend: price may ascend as a result of having broken its lower Bollinger Band on November 06, 2026
PTGX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 22 of 26 cases where PTGX's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PTGX's RSI Indicator exited the oversold zone, 17 of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 77%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 42 of 58 cases where PTGX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 72%.
Following a +3.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where PTGX advanced for three days, in 231 of 304 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 05, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PTGX as a result. In 68 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 72%.
The Moving Average Convergence Divergence Histogram (MACD) for PTGX turned negative on November 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 37 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
PTGX moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PTGX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock better than average.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. PTGX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 59 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 63 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (10.153) is normal, around the industry mean (3.498). PTGX has a moderately high P/E Ratio (108.230) as compared to the industry average of (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (34.130) is also within normal values, averaging (440.869).
KRYS | PTGX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 26 | 43 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 91 Overvalued | 97 Overvalued | |
PROFIT vs RISK RATING 1..100 | 9 | 5 | |
SMR RATING 1..100 | 46 | 59 | |
PRICE GROWTH RATING 1..100 | 54 | 44 | |
P/E GROWTH RATING 1..100 | 20 | 63 | |
SEASONALITY SCORE 1..100 | 2 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
KRYS's Valuation (91) in the Pharmaceuticals Major industry is in the same range as PTGX (97) in the Biotechnology industry. This means that KRYS’s stock grew similarly to PTGX’s over the last 12 months.
PTGX's Profit vs Risk Rating (5) in the Biotechnology industry is in the same range as KRYS (9) in the Pharmaceuticals Major industry. This means that PTGX’s stock grew similarly to KRYS’s over the last 12 months.
KRYS's SMR Rating (46) in the Pharmaceuticals Major industry is in the same range as PTGX (59) in the Biotechnology industry. This means that KRYS’s stock grew similarly to PTGX’s over the last 12 months.
PTGX's Price Growth Rating (44) in the Biotechnology industry is in the same range as KRYS (54) in the Pharmaceuticals Major industry. This means that PTGX’s stock grew similarly to KRYS’s over the last 12 months.
KRYS's P/E Growth Rating (20) in the Pharmaceuticals Major industry is somewhat better than the same rating for PTGX (63) in the Biotechnology industry. This means that KRYS’s stock grew somewhat faster than PTGX’s over the last 12 months.
| KRYS | PTGX | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 77% |
| Stochastic ODDS (%) | 2 days ago 80% | 2 days ago 72% |
| Momentum ODDS (%) | 2 days ago 74% | 2 days ago 72% |
| MACD ODDS (%) | 2 days ago 73% | 2 days ago 73% |
| TrendWeek ODDS (%) | 2 days ago 79% | 2 days ago 75% |
| TrendMonth ODDS (%) | 2 days ago 70% | 2 days ago 82% |
| Advances ODDS (%) | 2 days ago 79% | 2 days ago 76% |
| Declines ODDS (%) | 20 days ago 71% | 6 days ago 76% |
| BollingerBands ODDS (%) | 2 days ago 78% | 2 days ago 85% |
| Aroon ODDS (%) | 2 days ago 67% | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
KRYS’s FA Score shows that 2 FA rating(s) are green while PTGX’s FA Score has 1 green FA rating(s).
- KRYS’s FA Score: 2 green, 3 red.
- PTGX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
KRYS’s TA Score shows that 3 TA indicator(s) are bullish while PTGX’s TA Score has 4 bullish TA indicator(s).
- KRYS’s TA Score: 3 bullish, 4 bearish.
- PTGX’s TA Score: 4 bullish, 4 bearish.
Price Growth
KRYS (@Biotechnology) experienced а +0.48% price change this week, while PTGX (@Biotechnology) price change was -2.84% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -2.90%, and the average quarterly price growth was -13.48%.
Reported Earning Dates
KRYS is expected to report earnings on Mar 01, 2027.
PTGX is expected to report earnings on Mar 02, 2027.
Industries' Descriptions
@Biotechnology (+4.76% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
KRYS and
Correlation & Price change
A.I.dvisor indicates that over the last year, KRYS has been loosely correlated with VCYT. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if KRYS jumps, then VCYT could also see price increases.
| Ticker / NAME | Correlation To KRYS | 1D Price Change % | ||
|---|---|---|---|---|
| KRYS | 100% | +1.14% | ||
| VCYT - KRYS | 44% Loosely correlated | -7.18% | ||
| AXON - KRYS | 43% Loosely correlated | -0.21% | ||
| PTGX - KRYS | 41% Loosely correlated | +0.26% | ||
| CADL - KRYS | 41% Loosely correlated | -1.48% | ||
| REPL - KRYS | 39% Loosely correlated | +4.58% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ECNS | 26.54 | 0.04 | +0.15% |
| iShares MSCI China Small-Cap ETF (ECNS) | |||
| RCLR | 51.45 | N/A | N/A |
| Reckoner BBB-B Clo Reinvesting ETF | |||
| MOOD | 44.12 | -0.07 | -0.16% |
| Relative Sentiment Tactical Allocation ETF (MOOD) | |||
| RGEF | 33.96 | -0.13 | -0.38% |
| Rockefeller Global Equity ETF (RGEF) | |||
| IEI | 114.56 | -0.67 | -0.58% |
| iShares 3-7 Year Treasury Bond ETF (IEI) | |||